Atypical dyskinesias under treatment with antipsychotic drugs: Report from the AMSP multicenter drug safety project.

The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
Jessica BaumgärtnerSusanne Stübner

Abstract

The aim of this study was to describe atypical dyskinesias (AtypDs) occurring during treatment with antipsychotic drugs (APDs). AtypDs are dyskinesias showing either an unusual temporal relationship between onset of treatment and start of the adverse drug reaction (ADR) or an unusual presentation of clinical symptoms. Data on the utilisation of APDs and reports of severe APD-induced AtypDs were collected using data from the observational pharmacovigilance programme - 'Arzneimittelsicherheit in der Psychiatrie (English: drug safety in psychiatry)' (AMSP) - from 1993 to 2016. A total of 495,615 patients were monitored, of which 333,175 were treated with APDs. Sixty-seven cases (0.020%) of severe AtypDs under treatment with APDs were registered. The diagnoses of schizophrenic disorders as well as organic mental disorders were related to significantly higher rates of AtypDs. Second-generation antipsychotic drugs (SGAs) showed slightly higher rates of AtypDs (0.024%) than high-potency (0.011%) or low-potency first-generation antipsychotic drugs (FGAs; 0.006%). In 41 cases (61.2%), two or more drugs were found to cause AtypDs. Our study indicates that AtypDs are rare ADRs. SGAs may have a higher risk for the occurrence of AtypDs than...Continue Reading

References

Oct 1, 1979·The American Journal of Psychiatry·G Chouinard, B D Jones
Jan 1, 1979·Progress in Neuro-psychopharmacology·B BeckmannE Rüther
Oct 1, 1990·The British Journal of Psychiatry : the Journal of Mental Science·W M GlazerD C Moore
Jan 1, 1989·Psychosomatics·R J Koek, E H Pi
Jan 1, 1972·Zeitschrift für Neurologie·K EkbomL Ljungberg
Mar 1, 1969·British Medical Journal·N Hurwitz, O L Wade
Dec 1, 1980·Archives of General Psychiatry·J M Smith, R J Baldessarini
Jun 1, 1983·Clinical Neuropharmacology·D Tarsy
May 15, 1993·Statistics in Medicine·S E Vollset
Oct 1, 1996·Clinical Neuropharmacology·T HayashiS Yamawaki
Nov 14, 1997·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·L C Holloman, S R Marder
Jan 1, 1997·Schizophrenia Bulletin·M F EganR J Wyatt
Nov 13, 1998·The American Journal of Psychiatry·M G WoernerJ M Kane
Nov 25, 1998·Brain : a Journal of Neurology·V KiriakakisC D Marsden
Jul 6, 2000·The Australian and New Zealand Journal of Psychiatry·P S Sachdev
Nov 30, 2000·International Journal of Clinical Pharmacology and Therapeutics·G I KöhlerR H Böger
May 31, 2001·The Journal of Clinical Psychiatry·R Williams
Jan 5, 2002·CNS Drugs·Daniel TarsyFrank I Tarazi
Jan 5, 2002·The American Journal of Psychiatry·Christian R DolderDilip V Jeste
Jun 6, 2002·Schizophrenia Bulletin·Stephen R MarderNina R Schooler
Jan 1, 1964·Acta Psychiatrica Scandinavica·A FaurbyeH Pakkenberg
Aug 1, 1965·American Journal of Public Health and the Nation's Health·L G SEIDLL E CLUFF
Jan 2, 2004·The American Journal of Psychiatry·Sven JannoKristian Wahlbeck
Mar 31, 2004·Pharmacopsychiatry·R GrohmannH Hippius
Mar 31, 2004·Pharmacopsychiatry·R R EngelH Hippius
Mar 31, 2004·Pharmacopsychiatry·S StübnerE Rüther
Aug 3, 2004·The American Journal of Psychiatry·Mary V Seeman
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Dec 21, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Howard C MargoleseLawrence Annable
Mar 15, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Daniel Tarsy, Ross J Baldessarini
Dec 7, 2006·European Archives of Psychiatry and Clinical Neuroscience·Jose de Leon
Oct 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Del D MillerUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 8, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Maria Sierra PeñaJoseph Jankovic
Apr 19, 2011·Handbook of Clinical Neurology·Daniel TarsyRoss J Baldessarini
Nov 22, 2011·Practical Neurology·Tabish A Saifee, Mark J Edwards
Mar 24, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Michael J PelusoPeter B Jones
Aug 7, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·James T TeoKailash Bhatia
Jul 10, 2013·European Archives of Psychiatry and Clinical Neuroscience·R GrohmannS Stübner
Sep 28, 2013·Neuropsychiatric Disease and Treatment·Stacey K Jankelowitz
Dec 7, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Leslie J CloudStewart A Factor
Jul 6, 2014·BioMed Research International·Nevena DivacNatasa Cerovac
Jul 18, 2015·The Annals of Pharmacotherapy·Jessica M Hawthorne, Charles F Caley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

European Archives of Psychiatry and Clinical Neuroscience
Katrin DruschkySusanne Stübner
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
Katrin DruschkySermin Toto
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
Katrin DruschkyDetlef Degner
© 2021 Meta ULC. All rights reserved